The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP–PKA–EGFR–STAT3 axis

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

(2016) M. Nauck   DIABETES OBESITY & METABOLISM

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth

(2014) Takashi Nomiyama et al.   DIABETES

Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis

(2014) Zhuo Yu et al.   GUT

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

STAT3 Target Genes Relevant to Human Cancers

(2014) Richard Carpenter et al.   Cancers

Do GLP-1-Based Therapies Increase Cancer Risk?

(2013) M. A. Nauck et al.   DIABETES CARE

NAFLD in Asia—as common and important as in the West

(2013) Geoffrey C. Farrell et al.   Nature Reviews Gastroenterology & Hepatology

Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy

(2013) Takanori Hosokawa   WORLD JOURNAL OF GASTROENTEROLOGY

Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes

(2012) Z. F. Kang et al.   DIABETOLOGIA

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

(2012) Hsiao-Ping Chen et al.   GUT

The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells

(2011) Hagai Ligumsky et al.   BREAST CANCER RESEARCH AND TREATMENT

Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis

(2011) Ping Wang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Glucagon-Like Peptide-1 Receptor Activation Inhibits Growth and Augments Apoptosis in Murine CT26 Colon Cancer Cells

(2011) Jacqueline A. Koehler et al.   ENDOCRINOLOGY

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus

(2011) Chia-Hsuin Chang et al.   HEPATOLOGY

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

(2011) Goodarz Danaei et al.   LANCET

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

(2011) Gianluca Svegliati-Baroni et al.   LIVER INTERNATIONAL

Protein Kinase A in Cancer

(2011) Antonio Caretta et al.   Cancers

Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis

(2010) R. Fan et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis

(2010) Rohit Kohli et al.   HEPATOLOGY

Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC)

(2010) Yu Yang et al.   MEDICAL ONCOLOGY

Combined Targeting of Epidermal Growth Factor Receptor, Signal Transducer and Activator of Transcription-3, and Bcl-XL Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck

(2008) A. L. Boehm et al.   MOLECULAR PHARMACOLOGY

VIP inhibits human HepG2 cell proliferation in vitro

(2007) Afaf Absood et al.   REGULATORY PEPTIDES